Meeting
2013 Gastrointestinal Cancers Symposium
Significance of accurate HER2 testing as a new biomarker in advanced gastric cancer.
Authors
Tetsuya Kusumoto
Department of Surgery and Science, Kyushu Universi
Tetsuya Kusumoto , Hajime Ohtsu , Hiroyuki Kawano , Koji Ando , Satoshi Ida , Yasue Kimura , Hiroshi Saeki , Eiji Oki , Masaru Morita , Yoshihiko Maehara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 31, 2013 (suppl 4; abstr106)
DOI
10.1200/jco.2013.31.4_suppl.106
Abstract #
106
Poster Bd #
B50
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: Results of GASTric cancer HER2 reassessment study 3 (GASTHER3).
First Author: Seyoung Seo
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Computational pathology–based HER2 quantification to identify novel biomarkers in gastric cancer (GC).
First Author: Ansh Kapil
Poster
2020 ASCO Virtual Scientific Program
Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC).
First Author: Sun Young Rha
Poster
2019 ASCO Annual Meeting
A phase Ib study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.
First Author: Yee Chao